STOCK EXCHANGE RELEASE - OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE
19 SEPTEMBER 2022 at 9.30 EEST
165,797 Orion Corporation A shares converted into B shares
In accordance with Section 3 of the Articles of Association of Orion Corporation, 165,797 A shares have been converted into 165,797 B shares. The conversion has been entered into the Trade Register on 19 September 2022.
The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 34,310,524 A shares and 106,823,754 B shares. The number of votes of the company's shares is after the conversion 793,034,234.
Tuukka Hirvonen, Investor Relations, tel. +358 10 426 2721
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are oncology and pain. Orion's net sales in 2021 amounted to EUR 1,041 million and the company had about 3,350 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.